

IPCS

INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY

IPCS Harmonization Project

Guidance Document on Evaluating and Expressing Uncertainty in Hazard Characterization

SECOND EDITION 2017

IOMC

INTER-ORGANIZATION PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS

A cooperative agreement among FAO, ILO, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD



**World Health
Organization**

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization, the International Labour Organization or the United Nations Environment Programme.

Harmonization Project Document 11

GUIDANCE DOCUMENT ON EVALUATING AND EXPRESSING UNCERTAINTY IN HAZARD CHARACTERIZATION

This project was conducted within the IPCS project on the Harmonization of Approaches to the Assessment of Risk from Exposure to Chemicals.

Published under the joint sponsorship of the World Health Organization, the International Labour Organization and the United Nations Environment Programme, and produced within the framework of the Inter-Organization Programme for the Sound Management of Chemicals.

SECOND EDITION 2017



The **International Programme on Chemical Safety (IPCS)** was established in 1980. The overall objectives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequisite for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals.

This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations.

The **Inter-Organization Programme for the Sound Management of Chemicals (IOMC)** was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase international coordination in the field of chemical safety. The Participating Organizations are: FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organizations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment.

Guidance document on evaluating and expressing uncertainty in hazard characterization – 2nd edition

(IPCS harmonization project document ; no. 11)

ISBN 978-92-4-151354-8

© **World Health Organization, 2018**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Guidance document on evaluating and expressing uncertainty in hazard characterization– 2nd edition. Geneva: World Health Organization; 2018. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Printed in Switzerland

TABLE OF CONTENTS

FOREWORD	viii
FOREWORD TO THE SECOND EDITION 2018.....	ix
ACKNOWLEDGEMENTS.....	x
CONTRIBUTORS.....	xi
LIST OF ABBREVIATIONS.....	xvii
EXECUTIVE SUMMARY	xix
1. INTRODUCTION	1
1.1 Purpose and scope.....	1
1.2 Use of quantitative evaluation of uncertainties in hazard characterization to achieve better informed and more transparent decisions.....	2
1.3 Organization of this document.....	4
2. CONTEXT AND OVERVIEW	6
2.1 Uncertainty in hazard characterization evaluated in the context of problem formulation for risk assessment	6
2.2 Evaluation of uncertainty in hazard characterization in concert with other risk assessment methodologies	7
2.3 Overview of the principles and framework for evaluating uncertainty in hazard characterization	9
2.3.1 Principle 1: Individual-level effects (magnitude) and population-level effects (incidence) are conceptually distinct.....	9
2.3.2 Principle 2: For all types of end-points, the magnitude of effect M can be regarded as changing gradually	9
2.3.3 Principle 3: The concept of an “effect metric” for M forms the basis of “equipotency” and differences in “sensitivity”	10
2.3.4 Principle 4: Making inferences from a point of departure involves making adjustments and accounting for variability and uncertainty	10
2.3.5 Applying the framework.....	11
2.4 Implications for problem formulation and interaction with risk management	12
2.4.1 The target human dose HD_M^I as the focus of hazard characterization when evaluating uncertainties	12
2.4.1.1 A conceptual transition to the HD_M^I	12
2.4.1.2 Transition from the deterministic RfD to the HD_M^I as a natural extension of the transition from the NOAEL to the BMD.....	12
2.4.2 Being “conservative” and its relationship to evaluating uncertainty	15
2.4.2.1 “Conservative” in relation to protection goals.....	15
2.4.2.2 “Conservative” in relation to uncertainty: “coverage” and “degree of uncertainty”	15
2.4.3 Using conclusions from analysis of uncertainties to inform the question, “Do we know enough?”	17
2.4.4 How to adapt the approach for different regulatory contexts	18

3.	DETAILED DESCRIPTION OF THE APPROACH TO EVALUATING UNCERTAINTY IN HAZARD CHARACTERIZATION.....	19
3.1	Aspects of hazard characterization and associated uncertainties.....	19
3.2	A framework for evaluating uncertainty in hazard characterization based on four fundamental principles.....	21
3.2.1	Principle 1: Individual-level effects (magnitude) and population-level effects (incidence) are conceptually distinct.....	21
3.2.2	Principle 2: For all types of end-points, the magnitude of effect <i>M</i> can be regarded as changing gradually	22
3.2.2.1	Continuous end-points	22
3.2.2.2	Quantal end-points	23
3.2.3	Principle 3: The concept of an “effect metric” for <i>M</i> forms the basis of “equipotency” and differences in “sensitivity”	26
3.2.4	Principle 4: Making inferences from a point of departure involves making adjustments while accounting for uncertainty and variability	27
3.2.4.1	Uncertainty versus variability	27
3.2.4.2	Adjustment and uncertainty	28
3.3	Applying the framework	28
3.3.1	Quantifying uncertainties individually and in combination.....	28
3.3.1.1	Quantifying uncertainties individually	28
3.3.1.2	Combining uncertainties	29
3.3.2	Spreadsheet tool “APROBA” for facilitating approximate probabilistic analysis.....	30
3.4	Evaluation of other uncertainties	33
3.4.1	Uncertainties regarding distributions used in the probabilistic approach.....	33
3.4.2	Uncertainties regarding the assumption of independence	33
3.4.3	Uncertainties relating to qualitative aspects of hazard assessment.....	34
3.4.4	Uncertainties that are difficult to quantify	34
4.	IMPLEMENTATION OF THE APPROACH: PRELIMINARY UNCERTAINTY DISTRIBUTIONS.....	36
4.1	Using historical data: general approach.....	36
4.2	Points of departure	37
4.2.1	Benchmark dose.....	37
4.2.2	No-observed-adverse-effect level	37
4.2.3	Lowest-observed-adverse-effect level	39
4.3	Exposure duration	39
4.4	Interspecies extrapolation	40
4.4.1	Body size adjustment	41
4.4.1.1	Adjustment of oral doses	41
4.4.1.2	Uncertainty distribution for allometric scaling factor for oral doses.....	41
4.4.1.3	Body size adjustment of inhalation exposures and its uncertainty	41
4.4.2	Toxicokinetic/toxicodynamic differences.....	42
4.5	Human interindividual differences in sensitivity	43
4.5.1	Background on uncertainties in human interindividual differences	43
4.5.2	Uncertainty distributions for intraspecies variability.....	43
4.6	Route-to-route extrapolation.....	46

4.7	Summary of generic uncertainties per aspect	47
4.8	Evaluating primary uncertainty for other aspects	47
4.9	Chemical-specific distributions for primary uncertainties	49
4.10	Evaluating secondary uncertainties	50
5.	ILLUSTRATION OF THE APPROACH USING GENERIC HAZARD CHARACTERIZATION SCENARIOS	54
5.1	Probabilistic uncertainty characterization of the deterministic reference dose and derivation of a probabilistic reference dose	54
5.2	Sensitivity analysis: ranking the sources of uncertainty	57
5.3	Visualization of the uncertainty in the target human dose for different values of coverage and population incidence	58
6.	INTERPRETATION AND USE OF RESULTS.....	60
6.1	Setting a health-based guidance value	61
6.2	Acceptability and communication of health risks for a given situation.....	64
6.3	Prioritization of chemicals based on predicted risks.....	66
6.4	Socioeconomic analysis	66
7.	NEXT STEPS	68
7.1	Further research	68
7.1.1	Methodological issues.....	68
7.1.2	Input data	69
7.2	Implementation and dissemination	70
8.	REFERENCES.....	72
9.	GLOSSARY OF TERMS.....	76
ANNEX 1: COMBINING UNCERTAINTIES FOR THE THREE APPROACHES....		81
A1.1	General approach to combining uncertainties.....	81
A1.2	Non-probabilistic approach to combining uncertainties	82
A1.3	Approximate probabilistic approach to combining uncertainties	83
A1.4	Full probabilistic approach to combining uncertainties.....	85
ANNEX 2: APROBA SPREADSHEET TOOL USER GUIDE		87
A2.1	Introduction.....	87
A2.2	General layout of worksheets.....	87
A2.3	Step-by-step procedure for using APROBA.....	87
A2.4	Using intermediate calculations to estimate each aspect's contributions to uncertainty.....	91
A2.5	Visualizing the impact of changing coverage and incidence <i>I</i>	91

ANNEX 3: DETAILS OF ESTIMATING UNCERTAINTY DISTRIBUTIONS FOR USE OF A NO-OBSERVED-ADVERSE-EFFECT LEVEL, EXPOSURE DURATION, INTERSPECIES EXTRAPOLATION AND ROUTE-TO-ROUTE EXTRAPOLATION93

A3.1	Point of departure: uncertainty in using a NOAEL as a surrogate for a BMD	93
A3.1.1	Continuous end-points	93
A3.1.2	Quantal end-points	94
A3.2	Exposure duration: uncertainty in using a subchronic or subacute study as a surrogate for a chronic study.....	95
A3.2.1	Subchronic to chronic extrapolation	95
A3.2.2	Subacute to chronic extrapolation.....	97
A3.3	Interspecies extrapolation: uncertainty in using a test animal species as a surrogate for humans (after body size adjustment).....	98
A3.4	Route-to-route extrapolation: uncertainty in using an oral study as a basis for inhalation hazard, or vice versa	100
A3.5	References	101

ANNEX 4: DETAILED RESULTS OF ANALYSES OF HISTORICAL DATA ON INTRASPECIES HUMAN VARIABILITY104

A4.1	Introduction.....	104
A4.2	Observed intraspecies variation in toxicokinetics based on historical data.....	105
A4.3	Observed intraspecies variation in toxicodynamics based on historical data	107
A4.4	Estimated uncertainty in overall intraspecies variability	113
A4.5	References	115

ANNEX 5: CASE-STUDY: DEOXYNIVALENOL (DON).....116

A5.1	Introduction.....	116
A5.1.1	General note	116
A5.1.2	Problem formulation	116
A5.1.3	General approach	116
A5.2	Tier 1: Hazard characterization for general toxicity after repeated dosing using the NOAEL and default assessment factors.....	118
A5.2.1	Hazard characterization aspects	118
A5.2.1.1	Aspect I: Setting the PoD.....	118
A5.2.1.2	Aspect II: Adjustment of the PoD (LOAEL to NOAEL)	118

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26065

